Suchergebnisse - "Tymon-Rosario, Joan"

PubPharm (55)

1

Correction : Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer

enthalten in: British journal of cancer | 2024

von Roque, D. | Siegel, E. | Buza, N. | +18

ErratumFor: Br J Cancer. 2022 Jun;126(12):1695-1703. - PMID 35149854

2

Advances in antibody-drug conjugates for gynecologic malignancies

enthalten in: Current opinion in obstetrics & gynecology | 2023

von Tymon-Rosario, J. | Gorman, M. | Richardson, D. | +2

3

What role does adjuvant therapy play in the management of endometrial cancer?

enthalten in: Expert opinion on pharmacotherapy | 2023

von Huang, G. | Tymon-Rosario, J. | Santin, A.

4

Targeted Therapies in the Treatment of Uterine Serous Carcinoma

enthalten in: Current treatment options in oncology | 2022

von Tymon-Rosario, J. | Gorman, M. | Santin, A.

5

Targeted Therapies in the Treatment of Uterine Serous Carcinoma

enthalten in: Current treatment options in oncology | 2022

von Tymon-Rosario, J. | Gorman, M. | Santin, A.

6

Targeted Therapies in the Treatment of Uterine Serous Carcinoma

enthalten in: Current treatment options in oncology | 2022

von Tymon-Rosario, J. | Gorman, M. | Santin, A.

7

Targeted Therapies in the Treatment of Uterine Serous Carcinoma

enthalten in: Current treatment options in oncology | 2022

von Tymon-Rosario, J. | Gorman, M. | Santin, A.

8

Minimally Invasive Ovarian-Preserving Approach for the Management of a Sclerosing Stromal Tumor in an Adolescent : A Case Report

enthalten in: Journal of pediatric and adolescent gynecology | 2022

von Ahuja, C. | Tymon-Rosario, J. | Rottmann, D. | +3

9

Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu

enthalten in: Gynecologic oncology | 2022

von Yadav, G. | Roque, D. | Bellone, S. | +18

10

Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor

enthalten in: Gynecologic oncology | 2022

von Tymon-Rosario, J. | Manara, P. | Manavella, D. | +19

1
2
3
4
5
6
Nächster »
[6]